FDA Continues Important Steps to Ensure Quality, Safety and Effectiveness of Authorized COVID-19 Vaccines (EBS) (JNJ)

Emergent BioSolutions (EBS) PT Lowered to $67 at Cowen on FDA News

Cowen analyst Boris Peaker lowered the price target on Emergent BioSolutions (NYSE: EBS) to $67.00 (from $86.00) while maintaining a Market Perform rating.

The analyst commented, "The FDA released Form 483 detailing 9 observations of deficiency from a recent inspection at EBS's Bayview facility. We... More